Literature DB >> 30452225

Sea Urchin Embryo Model As a Reliable in Vivo Phenotypic Screen to Characterize Selective Antimitotic Molecules. Comparative evaluation of Combretapyrazoles, -isoxazoles, -1,2,3-triazoles, and -pyrroles as Tubulin-Binding Agents.

Marina N Semenova1, Dmitry V Demchuk2, Dmitry V Tsyganov2, Natalia B Chernysheva2, Alexander V Samet2, Eugenia A Silyanova2, Victor P Kislyi2, Anna S Maksimenko2, Alexander E Varakutin2, Leonid D Konyushkin2, Mikhail M Raihstat2, Alex S Kiselyov3, Victor V Semenov2.   

Abstract

A series of both novel and reported combretastatin analogues, including diarylpyrazoles, -isoxazoles, -1,2,3-triazoles, and -pyrroles, were synthesized via improved protocols to evaluate their antimitotic antitubulin activity using in vivo sea urchin embryo assay and a panel of human cancer cells. A systematic comparative structure-activity relationship studies of these compounds were conducted. Pyrazoles 1i and 1p, isoxazole 3a, and triazole 7b were found to be the most potent antimitotics across all tested compounds causing cleavage alteration of the sea urchin embryo at 1, 0.25, 1, and 0.5 nM, respectively. These agents exhibited comparable cytotoxicity against human cancer cells. Structure-activity relationship studies revealed that compounds substituted with 3,4,5-trimethoxyphenyl ring A and 4-methoxyphenyl ring B displayed the highest activity. 3-Hydroxy group in the ring B was essential for the antiproliferative activity in the diarylisoxazole series, whereas it was not required for potency of diarylpyrazoles. Isoxazoles 3 with 3,4,5-trimethoxy-substituted ring A and 3-hydroxy-4-methoxy-substituted ring B were more active than the respective pyrazoles 1. Of the azoles substituted with the same set of other aryl pharmacophores, diarylpyrazoles 1, 4,5-diarylisoxazoles 3, and 4,5-diaryl-1,2,3-triazoles 7 displayed similar strongest antimitotic antitubulin effect followed by 3,4-diarylisoxazoles 5, 1,5-diaryl-1,2,3-triazoles 8, and pyrroles 10 that showed the lowest activity. Introduction of the amino group into the heterocyclic core decreased the antimitotic antitubulin effect of pyrazoles, triazoles, and to a lesser degree of 4,5-diarylisoxazoles, whereas potency of the respective 3,4-diarylisoxazoles was increased.

Entities:  

Keywords:  antimitotic; combretastatins; diarylazoles; microtubule destabilization; sea urchin embryo

Mesh:

Substances:

Year:  2018        PMID: 30452225     DOI: 10.1021/acscombsci.8b00113

Source DB:  PubMed          Journal:  ACS Comb Sci        ISSN: 2156-8944            Impact factor:   3.784


  5 in total

Review 1.  Application of triazoles as bioisosteres and linkers in the development of microtubule targeting agents.

Authors:  M Shaheer Malik; Saleh A Ahmed; Ismail I Althagafi; Mohammed Azam Ansari; Ahmed Kamal
Journal:  RSC Med Chem       Date:  2020-01-29

2.  Synthesis, Screening and Characterization of Novel Potent Arp2/3 Inhibitory Compounds Analogous to CK-666.

Authors:  Artem I Fokin; Roman N Chuprov-Netochin; Alexander S Malyshev; Stéphane Romero; Marina N Semenova; Leonid D Konyushkin; Sergey V Leonov; Victor V Semenov; Alexis M Gautreau
Journal:  Front Pharmacol       Date:  2022-05-30       Impact factor: 5.988

3.  Synthesis and Antiproliferative Activity of Triphenylphosphonium Derivatives of Natural Allylpolyalkoxybenzenes.

Authors:  Dmitry V Tsyganov; Alexander V Samet; Eugenia A Silyanova; Vladimir I Ushkarov; Alexander E Varakutin; Natalia B Chernysheva; Roman N Chuprov-Netochin; Andrey A Khomutov; Anna S Volkova; Sergey V Leonov; Marina N Semenova; Victor V Semenov
Journal:  ACS Omega       Date:  2022-01-24

4.  Live imaging of echinoderm embryos to illuminate evo-devo.

Authors:  Vanessa Barone; Deirdre C Lyons
Journal:  Front Cell Dev Biol       Date:  2022-09-15

5.  A Survey on Tubulin and Arginine Methyltransferase Families Sheds Light on P. lividus Embryo as Model System for Antiproliferative Drug Development.

Authors:  Maria Antonietta Ragusa; Aldo Nicosia; Salvatore Costa; Caterina Casano; Fabrizio Gianguzza
Journal:  Int J Mol Sci       Date:  2019-04-30       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.